Format

Send to

Choose Destination
World J Gastroenterol. 2014 Apr 14;20(14):3738-50. doi: 10.3748/wjg.v20.i14.3738.

Colorectal cancer and immunity: what we know and perspectives.

Author information

1
Simon Pernot, Orianne Colussi, Julien Taieb, Service d'Hépatogastro-entérologie et d'oncologie digestive, Hôpital Européen Georges-Pompidou, Université Paris Descartes, Sorbonne Paris Cité, 75015 Paris, France.

Abstract

Strong evidence supports the concept of immunosurveillance and immunoediting in colorectal cancer. In particular, the density of T CD8⁺ and CD45⁺ lymphocyte infiltration was recently shown to have a better prognostic value than the classic tumor node metastasis classification factor. Other immune subsets, as macrophages, natural killer cells or unconventionnal lymphocytes, seem to play an important role. Induction of regulatory T cells (Tregs) or immunosuppressive molecules such as PD-1 or CTLA-4 and downregulation of antigen-presenting molecules are major escape mechanisms to antitumor immune response. The development of these mechanisms is a major obstacle to the establishment of an effective immune response, but also to the use of immunotherapy. Although immunotherapy is not yet routinely used in colorectal cancer, we now know that most treatments used (chemotherapy and biotherapy) have immunomodulatory effects, such as induction of immunogenic cell death by chemotherapy, inhibition of immunosuppression by antiangiogenic agents, and antibody-dependent cytotoxicity induced by cetuximab. Finally, many immunotherapy strategies are being developed and tested in phase I to III clinical trials. The most promising strategies are boosting the immune system with cytokines, inhibition of immunoregulatory checkpoints, vaccination with vectorized antigens, and adoptive cell therapy. Comprehension of antitumor immune response and combination of the different approaches of immunotherapy may allow the use of effective immunotherapy for treatment of colorectal cancer in the near future.

KEYWORDS:

Colorectal cancer; Immunity; Immunoregulation; Immunotherapy; Vaccination

PMID:
24833840
PMCID:
PMC3983433
DOI:
10.3748/wjg.v20.i14.3738
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center